Narula N, Wong ECL, AlRamdan R, et al. - Researchers undertook this retrospective observational study to assess the effectiveness as well as safety of higher maintenance dose regimens of adalimumab vs standard doses in Crohn disease (CD) patients who failed anti-TNF. Depending on post-induction maintenance regimen, patients with CD who failed anti-TNF and treated with adalimumab were grouped: 40mg subcutaneous (sc) weekly or 80mg sc every other week were defined as a high dose (HD) maintenance regimen and 40 mg sc every other week was described as a standard dose (SD) maintenance regimen. According to the findings, longer time-to-failure was observed in relation to HD maintenance regimens, vs SD regimens, in CD patients who failed anti-TNF.